Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Addex Therapeutics' Accounts Payables rose 4361.0% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 4361.0%. This contributed to the annual value of $903435.7 for FY2024, which is 6597.02% down from last year.
  • Per Addex Therapeutics' latest filing, its Accounts Payables stood at $1.5 million for Q3 2025, which was up 4361.0% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Accounts Payables ranged from a high of $4.2 million in Q2 2022 and a low of $907266.7 during Q4 2024
  • Its 4-year average for Accounts Payables is $2.4 million, with a median of $2.7 million in 2023.
  • The largest annual percentage gain for Addex Therapeutics' Accounts Payables in the last 5 years was 4361.0% (2025), contrasted with its biggest fall of 7222.5% (2025).
  • Quarter analysis of 4 years shows Addex Therapeutics' Accounts Payables stood at $3.1 million in 2022, then decreased by 13.57% to $2.7 million in 2023, then plummeted by 66.25% to $907266.7 in 2024, then skyrocketed by 60.84% to $1.5 million in 2025.
  • Its Accounts Payables stands at $1.5 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.1 million for Q1 2025.